Drs. Liu, Brady and Matulonis from Dana Farber, recently presented their findings on a phase III study looking at recurrent, platinum-sensitive ovarian cancer (OC) at this year's ASCO Virtual Scientific Program.
The study looked at treating recurrent OC with three different treatment options: platinum based chemo, treatment with olaparib (PARP inhibitor) or olaparib plus cediranib (anti-angiogenic).
The study did not meet its primary endpoint of progression-free survival but the authors felt that the results showed a comparable effect to the more traditional platinum based chemo. Of note however, the combination of olaparib and cediranib were more successful in patients with germ-line BRCA mutations.
To read more about the study, follow this link.
In October 2012, a dream was realized for two dynamic ovarian cancer survivors: Anne Tonachel and Robin Bray. Their dream was to provide a restorative retreat for other ovarian cancer survivors in the northeast. When the amazing Kennedy family of Camp Kieve and The Kennedy Learning Center provided the retreat space (in honor of a family member with ovarian cancer), this restorative retreat was born.
No comments:
Post a Comment